Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct...
| Published in: | Cells |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/6/1541 |
| _version_ | 1850071845482528768 |
|---|---|
| author | Norah Aldrak Sarah Alsaab Aliyah Algethami Deepak Bhere Hiroaki Wakimoto Khalid Shah Mohammad N. Alomary Nada Zaidan |
| author_facet | Norah Aldrak Sarah Alsaab Aliyah Algethami Deepak Bhere Hiroaki Wakimoto Khalid Shah Mohammad N. Alomary Nada Zaidan |
| author_sort | Norah Aldrak |
| collection | DOAJ |
| container_title | Cells |
| description | With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct killing of cancer cells and the activation of the host immunity to recognize and attack the tumor. Different variants of oHSV have been developed to optimize its antitumor effects. In this review, we discuss the development of oHSV, its antitumor mechanism of action and the clinical trials that have employed oHSV variants to treat different types of tumor. |
| format | Article |
| id | doaj-art-fa2ec67a3b744632b8a8e96d2fcfc8a8 |
| institution | Directory of Open Access Journals |
| issn | 2073-4409 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| spelling | doaj-art-fa2ec67a3b744632b8a8e96d2fcfc8a82025-08-20T00:17:01ZengMDPI AGCells2073-44092021-06-01106154110.3390/cells10061541Oncolytic Herpes Simplex Virus-Based Therapies for CancerNorah Aldrak0Sarah Alsaab1Aliyah Algethami2Deepak Bhere3Hiroaki Wakimoto4Khalid Shah5Mohammad N. Alomary6Nada Zaidan7Center of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11451, Saudi ArabiaCenter of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11451, Saudi ArabiaCenter of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11451, Saudi ArabiaCenter for Stem Cell Therapeutics and Imaging (CSTI), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USACenter for Stem Cell Therapeutics and Imaging (CSTI), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USACenter for Stem Cell Therapeutics and Imaging (CSTI), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USACenter of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11451, Saudi ArabiaCenter of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11451, Saudi ArabiaWith the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct killing of cancer cells and the activation of the host immunity to recognize and attack the tumor. Different variants of oHSV have been developed to optimize its antitumor effects. In this review, we discuss the development of oHSV, its antitumor mechanism of action and the clinical trials that have employed oHSV variants to treat different types of tumor.https://www.mdpi.com/2073-4409/10/6/1541oncolytic herpes simplex virus (oHSV)virotherapyimmunotherapycancer |
| spellingShingle | Norah Aldrak Sarah Alsaab Aliyah Algethami Deepak Bhere Hiroaki Wakimoto Khalid Shah Mohammad N. Alomary Nada Zaidan Oncolytic Herpes Simplex Virus-Based Therapies for Cancer oncolytic herpes simplex virus (oHSV) virotherapy immunotherapy cancer |
| title | Oncolytic Herpes Simplex Virus-Based Therapies for Cancer |
| title_full | Oncolytic Herpes Simplex Virus-Based Therapies for Cancer |
| title_fullStr | Oncolytic Herpes Simplex Virus-Based Therapies for Cancer |
| title_full_unstemmed | Oncolytic Herpes Simplex Virus-Based Therapies for Cancer |
| title_short | Oncolytic Herpes Simplex Virus-Based Therapies for Cancer |
| title_sort | oncolytic herpes simplex virus based therapies for cancer |
| topic | oncolytic herpes simplex virus (oHSV) virotherapy immunotherapy cancer |
| url | https://www.mdpi.com/2073-4409/10/6/1541 |
| work_keys_str_mv | AT norahaldrak oncolyticherpessimplexvirusbasedtherapiesforcancer AT sarahalsaab oncolyticherpessimplexvirusbasedtherapiesforcancer AT aliyahalgethami oncolyticherpessimplexvirusbasedtherapiesforcancer AT deepakbhere oncolyticherpessimplexvirusbasedtherapiesforcancer AT hiroakiwakimoto oncolyticherpessimplexvirusbasedtherapiesforcancer AT khalidshah oncolyticherpessimplexvirusbasedtherapiesforcancer AT mohammadnalomary oncolyticherpessimplexvirusbasedtherapiesforcancer AT nadazaidan oncolyticherpessimplexvirusbasedtherapiesforcancer |